Updated:
Beijing Jiakesi New Drugs Development Co.
Beijing Jiakesi New Drugs Development Co. is a Chinese firm headquartered in Beijing, registered as a drug development company. Its founding year and...
Overview
Beijing Jiakesi New Drugs Development Co. is a Chinese firm headquartered in Beijing, registered as a drug development company. Its founding year and principals are not publicly documented, and no wealth origin is disclosed. The entity operates within China's pharmaceutical sector, a landscape shaped by government initiatives like the 'Healthy China 2030' plan. The firm's strategy centers on new drug development, covering stages from preclinical research through clinical trials, with a focus on therapeutic areas common in the Chinese market. China's pharmaceutical R&D spending reached approximately $29.Its geographic footprint appears limited to China, without known international offices. No team size, additional offices, or affiliated vehicles are disclosed. The firm operates without publicly visible credentials or recent operational events. No verified recent activity or named portfolio companies are available from public records. A structural differentiator remains unclear due to sparse public information. In a competitive Chinese drug development sector, the firm's positioning relative to state-owned enterprises or private biotechs cannot be assessed. Succession and governance structures are unconfirmed.
General information
Firm type
Clinical-stage oncology drug developer
Year founded
2015
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Sector focus
Frequently asked questions
Is there any publicly available information about Beijing Jiakesi New Drugs Development Co.'s funding or financials?
No financial data, including AUM, revenue, or investment amounts, is publicly disclosed. The firm's funding status remains unknown.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: